1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow Aggressive Variant Prostate Carcinoma: new trials by email Literature Review of Aggressive Variant Prostate Carcinoma trials Research Report on Aggressive Variant Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Ipilimumab, Valemetostat - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 65 | 2020-08-20 | 2026-11-17 |
Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1)
Adenocarcinoma (1) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1)
CTLA-4 Antigen (1) · Ipilimumab (1)
M.D. Anderson Cancer Center (1)
United States (1)
Ana Aparicio (1)